Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws
TORONTO, ON / ACCESSWIRE / November 24, 2020 / Novamind Ventures Inc. (“Novamind”), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced that Reid Robison, MD, MBA, Chief Medical Officer of Novamind and Adele Lafrance, PhD, Consulting Research Scientist to Novamind, will present on a panel titled ‘Psychedelic-Assisted Psychotherapy for Eating Disorders and Cognitive Behavioral Therapies for PTSD + MDMA,’ hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”) Canada on November 24th from 5:00-6:30 pm PST.
In this webinar, participants will hear from Novamind’s preeminent experts in the field of clinical psychedelic research as they discuss a MAPS-sponsored clinical trial investigating MDMA-assisted psychotherapy for the treatment of eating disorders. Dr. Robison is the coordinating investigator of the trial, and Dr. Lafrance is the clinical investigator and strategy lead.
Dr. Robison co-founded Cedar Psychiatry LLC and Cedar Clinical Research LLC, organizations that were acquired by Novamind in July 2020. He has led over 100 clinical trials in neuropsychiatry and has guided thousands of ketamine-assisted psychotherapy sessions.
Dr. Lafrance is a leader in the research and clinical practice of psychedelic medicine with a focus on ayahuasca, MDMA, and psilocybin. She is the co-developer of Emotion-Focused Family Therapy, a globally recognized treatment modality that supports the involvement of family caregivers in their loved one’s recovery from mental health issues.
The online discussion is part of MAPS Canada’s 15-week long webinar series, ‘Examining The Psychedelic Renaissance!’, featuring scientists, doctors, visionaries, researchers and industry leaders such as Mark Haden, Executive Director, MAPS Canada; Rick Doblin, Founder, MAPS; Dr. Dennis McKenna, Ethnopharmacologist, Founding Member, Heffter Research Institute and Founder of McKenna Academy; and Paul Stamets, Speaker, Author, Mycologist, Medical Researcher, Entrepreneur.
For information on the webinar and participation, please visit https://mapscanada.org/webinar/episode-10/
Founded in 2019, Novamind is building a global network of infrastructure to serve the regulated psychedelics industry. With our wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind is dedicated to providing access to safe and legal psychedelic experiences, while advancing research for psychedelic medicine.
For more information visit www.novamind.ca.
CEO and Director
Telephone: +1 (647) 953 9512
KCSA Strategic Communications email@example.com
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.